Table 2. Summary of serum oxylipins in women with and without endometriosis at different menstrual phases.
| Analyte | % change of EM−(Prol)/EM−(Secr) | EM− Prol vs Secr (p-value) | % change of EM+Mild (Prol)/EM+Mild (Secr) | EM+Mild Prol vs Secr (p-value) | % change of EM+Sev (Prol)/EM+Sev (Secr) | EM+Sev Prol vs Secr (p-value) |
|---|---|---|---|---|---|---|
| 9,10-DiHOME | −106.8 | 0.13 | 61.3 | 0.18 | 57.6 | 0.19 |
| 12,13-DiHOME | −70.3 | 0.07 | 57.3 | 0.12 | 45.4 | 0.13 |
| 5,6-DHET | 8.1 | 0.55 | −7.1 | 0.59 | 3.0 | 0.99 |
| 8,9-DHET | −3.5 | 0.81 | −43.3 | 0.99 | −6.5 | 0.55 |
| 11,12-DHET | −12.8 | 0.45 | −34.8 | 0.68 | −27.3 | 0.07 |
| 14,15-DHET | −23.0 | 0.19 | −46.6 | 0.27 | −30.4 | 0.03 |
| 5-HETE | 34.6 | 0.15 | −0.8 | 0.87 | 35.3 | 0.38 |
| 8-HETE | 54.7 | 0.04 | 61.0 | 0.36 | 115.6 | 0.11 |
| 11-HETE | 61.6 | 0.02 | 58.9 | 0.34 | 75.3 | 0.20 |
| 12-HETE | 43.5 | 0.23 | 35.9 | 0.55 | −43.1 | 0.30 |
| 13-HODE | 30.4 | 0.14 | 43.7 | 0.42 | 49.9 | 0.20 |
| 15-HETE | 57.6 | 0.03 | 62.2 | 0.30 | 80.6 | 0.18 |
| 20-HETE | −20.2 | 0.31 | −8.5 | 0.79 | −25.5 | 0.14 |
| 5-HEPE | 18.6 | 0.41 | −19.3 | 0.38 | 17.6 | 0.73 |
| 9-HODE | 27.2 | 0.12 | 21.4 | 0.80 | 39.1 | 0.26 |
| 9,10-EODE | 17.8 | 0.53 | 36.8 | 0.57 | −15.6 | 0.46 |
| 12,13-EODE | 3.4 | 0.94 | 40.1 | 0.49 | −12.8 | 0.49 |
| 5-OxoETE | 52.4 | 0.04 | 51.4 | 0.47 | 48.3 | 0.41 |
| AA | 5.4 | 0.25 | −13.9 | 0.71 | 1.5 | 0.98 |
| LA | 2.8 | 0.59 | −1.0 | 0.88 | 3.5 | 0.77 |
EM−, women without endometriosis; EM+Mild, women with rAFS I or II endometriosis; EM+Sev, women with rAFS III or IV endometriosis.
Prol, proliferative phase; Secr, secretory phase.
Bold, significantly changed oxylipin (% change > 50%, p < 0.05).